基因體市場能否重見曙光呢？

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

Following its conception more than a decade ago, the field of genomics excited the research community with the possibility of a faster, surer route to drug discovery, but this optimism has quickly faded and the industry is reassessing its prospects. To date, no genomics-derived product has successfully completed Phase III trials, and it will be another two to four years before a significant number of the genomics compounds now in early-stage development reach this critical juncture. In the meantime, genomics companies face the continuing challenge of supporting the cost of clinical development. In this report, we examine the success that the biotechnology industry, in contrast to the genomics industry, has had with drug discovery; profile today's genomics companies and their pipelines; provide a SWOT analysis of the strengths (S), weaknesses (W), opportunities (O), and threats (T) facing the genomics industry; describe the various strategies that companies are using to improve their financial situation and get products to market; and discuss the outlook for the genomics industry, including the development of personalized medicine and genomics-derived diagnostics

Table of Contents

The Early Promise of Genomics

Genomics Pales Compared with Biotech

Can Genomics Jumpstart a Broad Portfolio?

Genomics-Derived Clinical Pipelines

• Celera Genomics
• CuraGen
• deCode Genetics
• Exelixis
• ExonHit
• Human Genome Sciences and GlaxoSmithKline
• Rigel
• ZymoGenetics

SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Evolving Business Strategies

• Celera Genomics
• Millennium Pharmaceuticals
• HGS-CoGenesys
• Nuvelo
• Incyte Pharmaceuticals

Outlook

• Personalized Medicine
• Genomics-Derived Therapeutics
• Genomics-Derived Diagnostics

相關商品

以基因為基之藥物開發相關市場調查報告書

基於片段的藥物研發(FBDD):技術·用途·開發平台
Fragment-Based Drug Discovery: Technologies, Applications, and Pipelines
價格 : US $ 795
出版日期 : 2012年04月

離子通道篩選動向：2012年
Ion Channel Screening Trends 2012
價格 : US $ 2500
出版日期 : 2012年04月

新一代測序 (NGS) 市場技術 (前導序列等)，競爭企業 (Illumina，454 Roche，Life Science Technologies)，應用，各工具分析:全球的趨勢和未來預測 (2011∼2016年)
Next Generation Sequencing (NGS) Market by Technology (Pyrosequencing & Others), Competitors (Illumina, 454 Roche, Life Science Technologies), Applications and Tools - Global Trends and Forecasts (2011-2016)
價格 : US $ 4650
出版日期 : 2012年04月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

生物標記及診斷的產學共同研究:領導目標重新調整到良好的效果

Recalibrating Goals Can Lead to Better Outcomes in Academic/Industry Biomarker and Diagnostics Collaborations

價格 : US $ 4600

出版日期 : 2011年10月

自體免疫疾病生技藥品市場策略性概要

Strategic Overview of the Autoimmune Biologics Market

價格 : US $ 4600

出版日期 : 2011年09月

生技改良藥的成功:生技改良藥市場上新興企業及開發平台

Success with Biobetters: Young Biobetters Companies and Pipelines

價格 : US $ 4600

出版日期 : 2011年09月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!